Related Experiment Video
Updated: Oct 7, 2025
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Building a Foundation for Precision Onco-Nutrition: Docosahexaenoic Acid and Breast Cancer
Henry J Thompson1, Elizabeth S Neil1, John N McGinley1
1Cancer Prevention Laboratory, Colorado State University, Fort Collins, CO 80523, USA.
Abstract:
In vivo evidence of heterogeneous effects of n-3 fatty acids (N3FA) on cell signaling pathways associated with the reduced growth of breast cancer has been reported and is consistent with the expectation that N3FA will not exert uniform effects on all molecular subtypes of the disease. Similarly, available evidence indicates that many metabolites of N3FA are synthesized by mammalian cells and that they exert metabolite-specific biological activities. To begin to unravel the complex relationships among molecular subtypes and effects exerted by specific N3FA metabolites on those pathways, proof-of-concept experiments were conducted using cell lines representative of common molecular subtypes of human breast cancer. N3FA differed in anticancer activity with docosahexaenoic acid (DHA) having greater anticancer activity than eicosapentaenoic acid. 4-oxo-docosahexaenoic (4-oxo-DHA), a penultimate metabolite of 5-lipoxygenase mediated DHA metabolism, induced dose-dependent inhibition of cell number accumulation with apoptosis as a primary effector mechanism. Interrogation of protein expression data using the Ingenuity Pathway Analysis (IPA) bioinformatics platform indicated that 4-oxo-DHA differentially impacted six canonical pathways and the cellular functions they regulate across common molecular subtypes of breast cancer. This included the endocannabinoid pathway for cancer inhibition that has not been previously reported. These findings provide a rationale for juxtaposing molecular subtype targeted treatment strategies with the adjuvant use of specific N3FA metabolites as an example of precision onco-nutrition (PON) for the management and control of breast cancer.
Insights
n-3 fatty acids (N3FA) show varied effects on breast cancer subtypes. A specific metabolite, 4-oxo-docosahexaenoic acid (4-oxo-DHA), effectively inhibited cancer cell growth and induced apoptosis, suggesting potential for precision onco-nutrition.
Area of Science:
- Oncology
- Molecular Biology
- Nutritional Science
Background:
- n-3 fatty acids (N3FA) exhibit heterogeneous effects on breast cancer cell signaling pathways.
- N3FA metabolites possess distinct biological activities, necessitating investigation into their specific roles.
- Understanding the interplay between breast cancer molecular subtypes and N3FA metabolite actions is crucial.
Purpose of the Study:
- To investigate the differential effects of N3FA metabolites on breast cancer molecular subtypes.
- To identify specific N3FA metabolites with anticancer activity and their mechanisms of action.
- To explore the potential of precision onco-nutrition (PON) in breast cancer management.
Main Methods:
- Utilized cell lines representing common human breast cancer molecular subtypes.
- Compared the anticancer activities of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).
- Investigated the effects of 4-oxo-docosahexaenoic acid (4-oxo-DHA), a DHA metabolite, on cell proliferation and apoptosis.
- Employed Ingenuity Pathway Analysis (IPA) to analyze protein expression data and impacted canonical pathways.
Main Results:
- Docosahexaenoic acid (DHA) demonstrated greater anticancer activity than eicosapentaenoic acid (EPA).
- 4-oxo-docosahexaenoic acid (4-oxo-DHA) induced dose-dependent inhibition of cell number accumulation, primarily through apoptosis.
- 4-oxo-DHA differentially affected six canonical pathways across breast cancer subtypes, including the novel identification of its role in the endocannabinoid pathway for cancer inhibition.
Conclusions:
- Specific N3FA metabolites, like 4-oxo-DHA, exhibit distinct anticancer effects on breast cancer subtypes.
- The findings support the development of precision onco-nutrition (PON) strategies, combining targeted therapies with specific N3FA metabolites.
- This approach offers a novel avenue for the management and control of breast cancer through tailored nutritional interventions.
More Related Videos
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
13:43Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
Related Concept Videos
02:59Cancer Prevention
Some...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...